Suppr超能文献

一项评估肌肉浸润性膀胱癌手术及放化疗的前瞻性研究。

A prospective study evaluating surgery and chemo radiation in muscle invasive bladder cancer.

作者信息

Haresh K P, Julka P K, Sharma D N, Rath G K, Prabhakar R, Seth A

机构信息

Department of Radiotherapy, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi-110 029, India.

出版信息

J Cancer Res Ther. 2007 Apr-Jun;3(2):81-5. doi: 10.4103/0973-1482.34684.

Abstract

AIM

The aim of our study was to compare the two standard treatment approaches in muscle invasive carcinoma of urinary bladder--radical cystectomy and chemo radiation.

MATERIALS AND METHODS

Transitional cell carcinoma (TCC) of bladder of stages, T2 to T4, N0/N1/N2 and M0 were included in the study. Patients were allotted to two arms of the study. Arm A consisted of radical cystectomy. Adjuvant CMV chemotherapy was given for T3/T4 or Node positive disease only. Arm B received 2 cycles of neoadjuvant CMV chemo therapy followed by concurrent chemo radiation.

RESULTS

Forty-four patients were recruited into the study. Thirty patients in the surgical arm and 13 patients in the chemo radiation arm. The actuarial two-year survival rate in surgical arm is 56% while in chemo radiation arm it is 54%. There was no statistically significant difference in disease-free survival also between the two groups.

CONCLUSION

Chemo radiation yielded equivalent survival results with radical cystectomy. So it is worth giving preference to chemo radiation that will give a better quality of life for the patient.

摘要

目的

我们研究的目的是比较膀胱肌层浸润性癌的两种标准治疗方法——根治性膀胱切除术和化疗放疗。

材料与方法

研究纳入膀胱移行细胞癌(TCC),分期为T2至T4、N0/N1/N2和M0。患者被分配到研究的两个组。A组采用根治性膀胱切除术。仅对T3/T4期或淋巴结阳性疾病给予辅助性CMV化疗。B组接受2个周期的新辅助CMV化疗,随后进行同步化疗放疗。

结果

44例患者被纳入研究。手术组30例患者,化疗放疗组13例患者。手术组的精算两年生存率为56%,而化疗放疗组为54%。两组之间无病生存率也无统计学显著差异。

结论

化疗放疗与根治性膀胱切除术的生存结果相当。因此,值得优先选择化疗放疗,因为它能为患者提供更好的生活质量。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验